Skip to content

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Ian Lindeman, Christopher-Michael Gale, James G. Christensen, Takayuki Kosaka, Alison Holmes Tisch, Andrew M. Rogers, Federico Cappuzzo, Tony S.K. Mok, Charles Lee, Bruce Evan Johnson, Lewis C. Cantley, Pasi Antero Janne

Science · 2007 · 4,559 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N. I., Gale, C.-M., Zhao, X., Christensen, J. G., Kosaka, T., Tisch, A. H., Rogers, A. M., Cappuzzo, F., Mok, T. S., Lee, C., Johnson, B. E., Cantley, L. C., & Janne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), 1039–1043. https://doi.org/10.1126/science.1141478

In text: (Engelman et al., 2007)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.

  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987
  2. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001
  3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004
  4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy2004
  5. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989

Metadata from OpenAlex (CC0). Citations are generated from the published record.